News for Kiniksa Pharmaceuticals, Ltd. (KNSA)

”“ ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth ”“”“ ARCALYST 2025 expected net product reve

Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of 450% and 7.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -100% and 0.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The rising prevalence of urticaria is fueling market growth, with increased allergic responses and lifestyle shifts playing key roles. Advances in biologic...

Earnings call: Kiniksa Pharma's Q3 2024 shows strong ARCALYST sales growth

Oct 29, 2024 / 12:30PM GMTOperator Good day. And thank you for standing by. Welcome to the Kiniksa Pharmaceuticals third quarter, 2024 earnings conference call.

Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -1,700% and 1.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Kiniksa Pharmaceuticals COO sells shares worth over $437,000

Roth analysis: Has volatility created a trigger warning for stocks?

Does Kiniksa Pharmaceuticals, Ltd. (KNSA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Jul 23, 2024 / 12:30PM GMTOperator Good day and thank you for standing by. Welcome to Kiniksa Pharmaceuticals second-quarter 2024 earnings conference call. (Ope

Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of 33.33% and 23.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

– ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth –– ARCALYST 2024 expected net product...

Document UNITED STATES SECURITIES...

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.28% to 35,510.96 while the NASDAQ rose 0.91% to 14,187.05. The S&P 500, also rose, gaining, 0.48% to 4,576.60.

/PRNewswire/ -- DelveInsight's 'COVID-19 Competitive Landscape – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...

Read Comparing Sierra Oncology (NASDAQ:SRRA) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) at ETF Daily News

Read Stock Analysts’ Upgrades for April 27th (ABM, ADSK, AEM, AFIB, ARCC, AVY, BAM, BAM.A, BZLYF, CABGY) at ETF Daily News

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au...